Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year. The results also clear a path forward for Moderna’s combination jab targeting Covid-19 and influenza after the company voluntarily withdrew its application for U.S. approval of that shot. The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and Covid jab.
Moderna in May voluntarily withdrew